AbbVie (ABBV) is expected to reiterate its fiscal 2025 guidance, but there could be potential risk in its aesthetics business line, UBS said in a note Friday.
The analysts said that this quarter will "set the tone for consumer sentiment and growth of Aesthetics for the year." With the guidance premised on gradual improvement in market growth, they said that uncertainty in the current macro environment could present a risk.
In particular, they cited the tariffs on China impacting the company's aesthetics products, which could hinder growth in markets outside the US.
UBS lowered its 2025 revenue forecast for the company to $59.2 billion from $59.5 and earnings to $12.08 per share from $12.28 per share.
The brokerage has a neutral rating for AbbVie with a $190 price target.
Price: 175.67, Change: +1.47, Percent Change: +0.84
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。